Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.

Roering, Pia; Siddiqui, Arafat; Heuser, Vanina D; Potdar, Swapnil; Mikkonen, Piia; Oikkonen, Jaana; Li, Yilin; Pikkusaari, Sanna; Wennerberg, Krister; Hynninen, Johanna; Grenman, Seija; Huhtinen, Kaisa; Auranen, Annika; Carpén, Olli; Kaipio, Katja

Roering, Pia; Siddiqui, Arafat; Heuser, Vanina D; Potdar, Swapnil; Mikkonen, Piia; Oikkonen, Jaana; Li, Yilin; Pikkusaari, Sanna; Wennerberg, Krister; Hynninen, Johanna; Grenman, Seija; Huhtinen, Kaisa; Auranen, Annika; Carpén, Olli; Kaipio, Katja.

Affiliation

Roering P; Institute of Biomedicine and Finnish Cancer Center (FICAN) West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Siddiqui A; Institute of Biomedicine and Finnish Cancer Center (FICAN) West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Heuser VD; Institute of Biomedicine and Finnish Cancer Center (FICAN) West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Potdar S; High Throughput Biomedicine Unit, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Mikkonen P; Helsinki Institute of Life Science (HiLIFE), Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Oikkonen J; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Li Y; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pikkusaari S; Institute of Biomedicine and Finnish Cancer Center (FICAN) West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Wennerberg K; Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
Hynninen J; Department of Obstetrics and Gynecology, Turku University Hospital and University of Turku, Turku, Finland.
Grenman S; Department of Obstetrics and Gynecology, Turku University Hospital and University of Turku, Turku, Finland.
Huhtinen K; Institute of Biomedicine and Finnish Cancer Center (FICAN) West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Auranen A; Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Carpén O; Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
Kaipio K; Department of Pathology, Precision Cancer Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Front Oncol ; 12: 954430, 2022.

Article in En | MEDLINE | ID: mdl-36081565

Key words

adavosertib; drug screen; high-grade serous ovarian cancer (HGSOC); homologous recombination (HR); homologous recombination deficiency (HRD); homologous recombination proficient; patient-derived cell line; platinum-resistant ovarian cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google